Abstract
OBJECTIVES: This study aims to investigate the molecular mechanisms of the combination of stellasterin, quercetin, and kaempferol - components of the phytopreparation ginseng (trade name Panax) - in the treatment of tissue hypoxia occurring in patients with viral and bacterial pneumoni. METHODS: An analytical single-center method of network pharmacology was utilized, involving 110 individuals divided into two subgroups: placebo and Panax phytopreparation. The therapy course lasted 2 months, after which physical (forced vital capacity, respiratory volume, oxygen saturation) and laboratory (total ATPase, Na+/K+-ATPase, glucose, leukocytes) parameters were evaluated. RESULTS: The administration of kaempferol, stellasterin, and quercetin increased the activity of total ATPase compared to baseline measurements in pneumonia patients with respiratory insufficiency, as well as compared to the placebo group. Thus, phytopreparations capable of controlling or limiting inflammatory reactions in various types of pneumonia and accompanying hypoxia represent promising adjunctive therapy. CONCLUSIONS: Given the increasing incidence of viral and bacterial pneumonia, there is a growing need to develop new treatment strategies for patients and improve hypoxia outcomes.